Time filter

Source Type

Patent
Miltenyi Biotec GmbH | Date: 2017-01-11

A MEMS-based cell sorter is disclosed, which uses a novel combination of features to accomplish the cell sorting using a microfabricated cell sorting valve housed in a disposable cartridge. The features include an interposer that provides fluid communication between the microfluidic passages in the silicon substrate and a plurality of fluid reservoirs in the cartridge, including a sample, sort and waste reservoir The disposable cartridge may include other features that assist in the handling of small volumes of fluids, such as a siphon region in the sort reservoir and funnel-shaped regions in the sample and waste reservoirs. A mixing mechanism may be provided for stirring the contents of the sample reservoir.


Patent
Miltenyi Biotec GmbH | Date: 2017-03-01

The present invention provides a process for generation of genetically modified T cells, T cell subsets and/or T cell progenitors comprising the steps: a) providing a cell sample comprising T cells, T cell subsets and/or T cell progenitors b) preparation of the cell sample by centrifugation c) magnetic separation of the T cells, T cell subsets and/or T cell progenitors d) activation of the enriched T cells, T cell subsets and/or T cell progenitors using modulatory agents e) genetic modification of the T cells, T cell subsets and/or T cell progenitors f) expansion of the genetically modified T cells, T cell subsets and/or T cell progenitors in a cultivation chamber g) washing of the cultured T cells, T cell subsets and/or T cell progenitors characterized in that all steps are performed in a closed and sterile cell culture system.


Patent
Miltenyi Biotec GmbH | Date: 2017-01-11

A MEMS-based cell sorting systenn is disclosed, which uses a novel combination of features to accomplish the cell sorting in the microfabricated channels housed in a disposable cartridge. The MEMS-based cell sorting system may include a microfabricated cell sorting valve that is responsive to an applied magnetic field. The MEMS-based cell sorting system may further include an electromagnet that generates a magnetic field to actuate the microfabricated cell sorting valve. The electromagnet may have a design which allows it to create a very localized magnetic field while having adequate thermal properties to operate reliably.


Patent
Miltenyi Biotec GmbH | Date: 2016-10-25

The invention is directed to a Perfusion device for biological tissues comprising Use of the perfusion device in a process for disaggregation of a biological tissue to yield target cells.


Patent
Miltenyi Biotec GmbH | Date: 2017-05-24

The invention is directed to a Perfusion device for biological tissues comprising- a casing having two parts, a first part (1) and a second part (9),- a holder (7) for a plurality of hollow penetration structures (8), wherein the hollow penetration structures (8) are provided with at least one orifice having fluid communication through the holder (7)- a support (5) for the biological tissue (6)characterized in that the support (5) for the biological tissue (6) is positioned in the casing at a distance to the holder (7) that by joining the first part (1) and the second part (9) to form the casing, the hollow penetration structures (8) are in proximity to the holder (7). Use of the perfusion device in a process for disaggregation of a biological tissue to yield target cells.


The present invention provides a chimeric antigen receptor (CAR), comprising an extracellular part, at least one intracellular signaling domain, and at least one transmembrane domain, wherein the extracellular part of said CAR comprises a) at least one antigen binding domain, and b) at least one cytokine receptor activating or blocking domain. The invention also provides isolated nucleic acid molecule(s) encoding for the said CAR, a cell comprising said nucleic acid molecule(s), a cell expressing said CAR and therapeutic uses of said CAR.


Patent
Miltenyi Biotec GmbH | Date: 2017-01-11

The invention is directed to a process for sorting target cells and non-target cells from a sample by a cell sorting valve microfabricated on a surface of a silicon substrate, with microfabricated channels leading from the cell sorting valve, wherein the cell sorting valve separates the target particles from non-target material;a disposable cartridge containing a sample reservoir, a sort reservoir and a waste reservoir; wherein the sample is provided in a buffer comprising nuclease.


Grant
Agency: European Commission | Branch: H2020 | Program: IA | Phase: ICT-28-2015 | Award Amount: 10.29M | Year: 2016

Photonics is essential in todays life science technology. PIX4life will mature a state of the art silicon nitride (SiN) photonics pilot line for life science applications in the visible range and pave the way to make it accessible as an enabler for product development by a broad range of industrial customers. We aim at 1) establishing a validated CMOS compatible SiN technology platform in the visible range for complex densely integrated photonics integrated circuits (PICs), 2) developing a supply chain to integrate mature semiconductor laser sources and CMOS detector arrays with the SiN PICs on the basis of technologies that are scalable to high volume, 3) establishing appropriate design kits and tools, 4) demonstrating the performance of the pilot line for well-chosen life science applications in the domain of vital sensing, multispectral sources for super-resolution microscopy, cytometry and 3D tissue imaging, 5) setting up the logistics for multi-project-wafer (MPW) access to the pilot line. Integrated photonics has demonstrated that optical functions can be realized in a more compact, robust and cost-effective way by integrating functionalities on a single chip. At present industrialization is limited to telecom applications at infrared wavelengths. The field of life sciences is heavily dependent on bulky and expensive optical systems and would benefit enormously from low cost photonic implementations. However this field requires a visible light PIC-technology. Proof of concept demonstrations are abundant, but pilot line and manufacturing capacity is limited, inhibiting industrial take up. PIX4life will drive the future European RTD in visible photonic applications for life sciences by bridging technological research (via participation of 2 academic and 2 research institutes) towards industrial development (via participation of a foundry, two large companies and 9 fabless SMEs, either technology suppliers or life science end users).


Grant
Agency: European Commission | Branch: H2020 | Program: RIA | Phase: PHC-14-2015 | Award Amount: 7.47M | Year: 2016

Severe combined immunodeficiency (SCID) is a devastating rare disorder of immune system development. Affected infants are born without functional immune systems and die within the first year of life unless effective treatment is given. Treatment options are limited to allogeneic haematopoietic stem cell transplantation and autologous stem cell gene therapy. Over the last 15 years, gene therapy for two forms of SCID (SCID-X1 and ADA SCID) has shown significant safety and efficacy in correcting the immunodeficiency and allowing children to live normal lives. Proof of concept of gene therapy for 3 other SCID forms has also been shown by members of the proposed SCIDNET consortium and is ready for translation into clinical trials. We are therefore in a position whereby, over the next 4 years, we can offer gene therapy as a curative option for over 80% of all forms of SCID in Europe. Importantly for 1 of these conditions (ADA SCID) we will undertake clinical trials that will lead to marketing authorisation of the gene therapy product as a licensed medicine. In addition, we will investigate the future technologies that will improve the safety and efficacy of gene therapy for SCID. Our proposal addresses an unmet clinical need in SCID, which is classified as a rare disease according to EU criteria (EC regulation No. 141/2000). The proposal also addresses the need to develop an innovative treatment such as gene therapy from early clinical trials though to a licensed medicinal product through involvement with regulatory agencies and is in keeping with the ambitions of the IRDiRC. The lead ADA SCID programme has Orphan Drug Designation and clinical trial design is assisted by engagement with the European medicines Agency. The ADA SCID trial will act as a paradigm for the development of the technologies and processes that will allow gene therapy for not only SCID, but also other bone marrow disorders, to become authorised genetic medicines in the future.


Grant
Agency: European Commission | Branch: H2020 | Program: RIA | Phase: PHC-16-2015 | Award Amount: 5.99M | Year: 2016

Chimeric antigen receptors (CARs) are artificial surface receptors that can be introduced into somatic cells by genetic engineering and that act as recognition molecules like antibodies or T-cell receptors. In this respect, CARs are increasingly used for cellular therapy to redirect T-cells specifically towards killing of cancer cells. Recent success stories of cancer therapy with CAR modified T-cells have raised enormous scientific and public expectations to cure severely ill patients. However, there are still many obstacles to overcome for translation into clinics because the technology for GMP-compliant manufacture of genetically modified cellular products is extremely complex and expensive. Moreover, CAR therapy needs to be improved with respect to off-target activity, safety and potency. Consequently, the envisaged project is overall aiming at a particular technological breakthrough in cellular cancer therapy by delivering a comprehensive CARAT platform explicitly tailored for automated, easy-to-handle and cost-efficient manufacture of CAR-modified ATMP. Specifically, we aim: (a) to implement unique next-generation cell processing tools like the CliniMACS Prodigy (b) to develop advanced enabling technologies to obtain more effective and safer cellular products by improved gene delivery and innovative CARs design (c) to assemble tools and technologies towards an integrated CARAT process for automated GMP-compliant manufacture of gene-modified T-cells (d) to demonstrate proof-of-concept and regulatory compliance (e) to disseminate broadly applicable, simplified CAR T-cell technologies In summary, our vision is to overcome current hurdles for translation of cellular therapies and to elevate them to the next level of standard-of-care thus serving patients with so far incurable solid tumours and hematologic malignancies. Thereby, we will empower Europe to become a global leader in the development and commercialisation of CAR T-cell tools and technologies.

Loading Miltenyi Biotec GmbH collaborators
Loading Miltenyi Biotec GmbH collaborators